Peanut Allergy

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

2100%

+ 8 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

RegeneronTARRYTOWN, NY

1 program

DupilumabPhase 2Monoclonal Antibody

AnaptysBioSAN DIEGO, CA

1 program

EtokimabPhase 2Monoclonal Antibody1 trial

Active Trials

NCT02920021CompletedEst. Mar 2018

Allergy TherapeuticsUK - West Sussex

1 program

Peanut Protein 4,000mgPhase 21 trial

Active Trials

NCT02103270CompletedEst. Sep 2018

Vedanta BiosciencesMA - Cambridge

1 program

Vancomycin plus VE416 before PNOITPhase 1/21 trial

Active Trials

NCT03936998Unknown60Est. Jan 2024

COUR PharmaceuticalsIL - Skokie

2 programs

CNP-201Phase 11 trial

Active Trials

NCT04950504TerminatedEst. Jul 2022

NCT05250856TerminatedEst. Dec 2023

Hal AllergyNetherlands - Leiden

2 programs

HAL-MPE1Phase 11 trial

Active Trials

NCT02991885Completed42Est. Sep 2019

NCT02163018Completed17Est. Jun 2015

AstellasChina - Shenyang

1 program

ASP0892Phase 11 trial

Active Trials

NCT03755713Completed20Est. Oct 2021

IgGenixCA - South SF

1 program

IGNX001Phase 11 trial

Active Trials

NCT06331728CompletedEst. Nov 2025

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

AnaptysBioEtokimab

Allergy TherapeuticsPeanut Protein 4,000mg

Vedanta BiosciencesVancomycin plus VE416 before PNOIT

IgGenixIGNX001

COUR PharmaceuticalsCNP-201

AstellasASP0892

Hal AllergyHAL-MPE1

Clinical Trials (9)

Total enrollment: 139 patients across 9 trials

NCT02920021 AnaptysBioEtokimab

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

Start: Jan 2017Est. completion: Mar 2018

Phase 2Completed

NCT02103270 Allergy TherapeuticsPeanut Protein 4,000mg

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

Start: Apr 2014Est. completion: Sep 2018

Phase 2Completed

NCT03936998 Vedanta BiosciencesVancomycin plus VE416 before PNOIT

VE416 for Treatment of Food Allergy

Start: Jun 2019Est. completion: Jan 202460 patients

Phase 1/2Unknown

NCT06331728 IgGenixIGNX001

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

Start: Sep 2024Est. completion: Nov 2025

Phase 1Completed

NCT05250856 COUR PharmaceuticalsCNP-201

CNP-201 in Subjects With Peanut Allergy

Start: Mar 2022Est. completion: Dec 2023

Phase 1Terminated

NCT04950504 COUR PharmaceuticalsCNP-201

Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy

Start: Jun 2021Est. completion: Jul 2022

Phase 1Terminated

NCT03755713 AstellasASP0892

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Start: Mar 2019Est. completion: Oct 202120 patients

Phase 1Completed

NCT02991885 Hal AllergyHAL-MPE1

HAL-MPE1 Safety and Tolerability Study

Start: Dec 2016Est. completion: Sep 201942 patients

Phase 1Completed

NCT02163018 Hal AllergyHAL-MPE1

HAL-MPE1 First-in-human

Start: Jun 2014Est. completion: Jun 201517 patients

Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

8 companies competing in this space